1. Opus Genetics, Inc. (NASDAQ:IRD)
On March 2, 2026, BTIG raised the price target on Opus Genetics, Inc. (NASDAQ:IRD) to $12 from $7 and maintained a Buy rating. BTIG said the company’s investment story appears to be gaining momentum after the initial BEST1 correction patient exceeded expectations, with the highly visually impaired “sentinel patient” showing both the structural changes anticipated and signs of improved vision.
On February 27, 2026, Opus Genetics presented new clinical data from its ongoing Phase 1/2 study of OPGx-BEST1 gene therapy at the 49th Annual Meeting of the Macula Society in San Diego. Three-month results from the first adult participant showed the therapy was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities following subretinal administration. The sentinel participant, a 63-year-old female with Autosomal-Recessive Bestrophinopathy and severe functional impairment, showed early signals of functional vision improvement, including a 12-letter gain in Best Corrected Visual Acuity in the treated eye. Structural improvements were also observed, including a 23% decrease in central subfield thickness and resolution of intraretinal fluid in some areas.
On February 25, 2026, Opus Genetics said the U.S. FDA accepted for review the supplemental New Drug Application for phentolamine ophthalmic solution 0.75% for the treatment of presbyopia, assigning a PDUFA goal date of October 17, 2026. Recruitment in the Phase 1/2 OPGx-BEST1 study is ongoing at two U.S. clinical sites, with additional locations expected to open in Florida, Cincinnati, and New York.
Opus Genetics, Inc. (NASDAQ:IRD) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for inherited retinal diseases.
While we acknowledge the potential of IRD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRD and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
